Abstracts tagged "patient outcomes and rheumatic disease"

Abstract Number: 334 • 2018 ACR/ARHP Annual Meeting
Use of Handheld Device to Enhance Patient Reported Outcome Measure Data Collection in an Academic Rheumatology Practice
Vivek Nagaraja¹, Vladimir Ognenovski² and Dinesh Khanna¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Patient-reported outcome measures (PROMs) are accepted modalities of gathering patient self-report of their health status in the realms of physical, mental and social well-being.…
Abstract Number: 1413 • 2016 ACR/ARHP Annual Meeting
Establishing Clinical Severity for Patient Reported Outcomes Measurement Information System Measures in Adult Patients with Rheumatic Diseases
Vivek Nagaraja¹, Constance Mara², Carole V. Dodge³, David Fox⁴, Puja Khanna⁵, Timothy Laing⁴, W Joseph McCune⁶, Rajaie Namas⁴, Debra Bancroft Rizzo⁴, Kelly Vanoverbeke⁴, Amber Young⁷, Maha Almackenzie¹ and Dinesh Khanna⁸, ¹Department of Medicine [Division of Rheumatology], University of Toledo, Toledo, OH, ²James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Physical Medicine and Rehabilitation [Occupational Therapy], University of Michigan, Ann Arbor, MI, ⁴Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ⁵Rheumatology, University of Michigan, Ann Arbor, MI, ⁶Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ⁷Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁸University of Michigan, Ann Arbor, MI
Background/Purpose: Different patient reported outcome [PRO] measures are used for rheumatic diseases [RD], and there is lack of uniform generic illness measures across the disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].